美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请

2020-12-12 JACKZHAO MedSci原创

美国FDA正式批准辉瑞和BioNTech的新冠疫苗紧急使用授权(EUA)申请。

12月11日,美国FDA 正式批准辉瑞疫苗(BNT162b2)紧急使用,第一批共290万剂疫苗将从下周一起开始运送至美国各地,成为美国抗疫进程中重大里程碑。

美国推特FDA及网站截图

这一决定,美国成为对该疫苗进行紧急使用授权的第六个国家,此前为英国、巴林、加拿大、沙特阿拉伯和墨西哥。预计将在数周内获得包括欧盟在内的其他国家与地区授权。

紧急使用授权(EUA)含义是指,FDA授予该医疗产品的特殊授权,可在紧急情况下使用但尚未完全批准。辉瑞公司必须为其疫苗单独提交一份申请,以得到FDA的完全许可。

FDA官网发布的声明指出,确定批准辉瑞-BioNTech新冠疫苗是因为其已符合签发EUA的法定标准。有数据证明辉瑞-BioNTech 新冠疫苗可能有效预防新冠肺炎数据还支持已知和潜在的利益大于已知和潜在的风险,从而支持疫苗在16岁及以上的数百万人中使用,包括健康个体。在做出此决定时,FDA可以向公众和医学界保证,它已经对可用的安全性,有效性和制造质量信息进行了彻底的评估。

Stephen M. Hahn推特截图

FDA局长Stephen M. Hahn表示:“今天的行动遵循公开透明的审查程序,其中包括来自独立科学和公共卫生专家的意见,并由该机构的职业科学家进行了全面评估,以确保该疫苗符合FDA的安全性、有效性和制造质量标准,以支持紧急使用授权。以预防新兴疾病威胁,这是对全球科学创新和公私合作的真实证明。

总体与亚组疫苗保护效力情况,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,DOI: 10.1056/NEJMoa2034577

该决定是辉瑞及其德国合作伙伴BioNTech的胜利,后者在11个月前就开始研发这款疫苗。疫苗通常需要数年才能开发出来。该公司的后期临床试验招募了近44000人,被发现有95%的有效率。

此前一天,疫苗和相关生物制品咨询委员会(Vaccines and Related Biological Products Advisory Committee)的投票结果为17票赞成、4票反对、1票弃权通过辉瑞公司针对16岁及16岁以上人群使用的疫苗,该机构计划在周六发布正式授权。

美国总统特朗普推特截图

但在特朗普总统因未能更快地批准疫苗而攻击哈恩博士之后,该时间表缩短了半天。 但是,加速的公告预计不会加快全国疫苗的交付。特朗普周五星期五在推特上对FDA局长Stephen M. Hahn写道,在“我的推动”下,政府已将疫苗开发工作缩短了数年。 “现在该拿出疫苗了!” “停止玩游戏,开始挽救生命!!!” 特朗普总统此前也一再指责美国FDA以及制药商们,缓慢进行审批程序,以便从政治上伤害他。

辉瑞疫苗如何运输,CNN

据《纽约时报》报道,辉瑞公司已与美国政府达成协议,将在明年3月前提供1亿剂这种疫苗。根据该协议,这些疫苗将免费向公众提供。

随着疫苗剂量在美国全国范围内分配,各州和地方官员将监督疫苗在各州以及物流中的分配,并且优先考虑卫生保健工作者和长期护理设施的居民。

在大多数情况下,首批疫苗将从辉瑞位于密歇根州卡拉马祖的工厂运输到医院系统和药房。据CNN报道,各州已制定了个性化的疫苗分配计划,该计划随每个州的人口和地理需求而略有不同。美国CDC疾病预防控制中心的官员一直与州领导人保持密切联系,以了解他们的分配计划将如何运作以及可能导致州与州之间出现挑战。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2022-02-16 普外科医师

    厉害

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2021-01-17 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 瓜虫

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 550255731

    希望有用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 胎胎

    里程碑!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 355366180

    有担当

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 言西早

    美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 yangchou

    疫苗和抗疫措施并施才能控制疫情。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1193859, encodeId=bb1f1193859a9, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85f65311925, createdName=普外科医师, createdTime=Wed Feb 16 07:23:04 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059320, encodeId=1e472059320a5, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 17 20:54:27 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523325, encodeId=248b1523325ad, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Mon Dec 14 03:54:27 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907384, encodeId=b44890e38407, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=568f2273884, createdName=瓜虫, createdTime=Sat Dec 12 20:11:18 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907326, encodeId=5c9890e326ef, content=希望有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201212/339d104ab4ab4fb380429fa40b639709/1997bbda7d9c4bea8db803e128975f59.jpg, createdBy=b5693046539, createdName=550255731, createdTime=Sat Dec 12 16:42:25 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907308, encodeId=868c90e30885, content=里程碑!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SUJcTwXicljbKGJibCoQZE6Q4Qn5cogUOWth91eb3XIFk8sJ4IRn2a3W9WegJyEkwNMGcr1Hsxt9azlSQric4uPWg/132, createdBy=b9bd2355820, createdName=胎胎, createdTime=Sat Dec 12 14:43:33 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907305, encodeId=4d7f90e30501, content=有担当, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Dec 12 14:17:52 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907293, encodeId=f84590e293a6, content=美国抗疫重大里程碑:FDA正式批准辉瑞疫苗紧急使用授权申请。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Sat Dec 12 13:18:43 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907287, encodeId=9c6f90e287f7, content=疫苗和抗疫措施并施才能控制疫情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Dec 12 12:58:10 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907285, encodeId=d4cb90e285eb, content=里程碑, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Dec 12 12:55:19 CST 2020, time=2020-12-12, status=1, ipAttribution=)]
    2020-12-12 神盾医疗局局长Jack

    里程碑

    0

相关资讯

cell:室温下能存放至少一周!秦成峰/英博/王佑春团队开发新型mRNA新冠疫苗

今日,《细胞》杂志在线发表了一篇关于新冠疫苗的最新论文。由秦成峰研究员、英博博士以及王佑春研究员共同领导的一支团队,开发出了一款新型的mRNA新冠疫苗。

Nat Struct Mol Biol:钱书兵组揭示5'UTR在mRNA翻译和稳定性中的作用

,mRNA究竟何时被当做模板被翻译以及何时被认为不再需要被降解因子分解,还有哪些mRNA容易或者难以被翻译,哪些mRNA容易被降解,潜在的机制又是什么,这些问题一直困扰着我们。

NEJM:mRNA疫苗mRNA-1273用于新冠肺炎的预防研究

mRNA-1273疫苗可诱导了抗SARS-CoV-2免疫应答,疫苗的安全性和耐受性良好,有进一步开发的潜力

J Periodontal Res:种植体周围炎与牙周炎的lncRNA和mRNA表达谱的分析

种植体周围炎是一种菌斑生物膜介导的感染性疾病,会导致种植体周围牙槽骨的吸收。与牙周炎相比,种植体周围炎侵袭性更强,进展较快,治疗效果较难预测。

Circulation:Regnase-1通过介导细胞因子mRNA降解抑制衰竭心脏的无菌性炎症

促炎细胞因子在心力衰竭的发病机制中起着重要作用。衰竭心脏内维持无菌性炎症的机制仍不明确。虽然转录调控对促炎细胞因子基因表达很重要,但mRNA的稳定性也有助于免疫反应的动态。Regnase-1是一种RNase,参与免疫细胞中一系列促炎细胞因子mRNA的降解。但Regnase-1在非免疫细胞(如心肌细胞)中的作用仍有待阐明。为了研究Regnase-1在心肌细胞中介导促炎细胞因子降解的作用,研究人员建立

Nat Commun:新冠病毒难攻克的原因找到了!原来是模仿人mRNA“帽子结构”

原来,SARS-CoV-2能模拟人的mRNA修饰过程来“伪装”自己,从而顺利地逃过免疫系统的识别。揭示了病毒mRNA加帽封端的具体机制并发现了可用于治疗的抗病毒位点。

拓展阅读

Nature:癌症免疫治疗的未来:疫苗的力量

从20世纪末的初步探索到21世纪的技术革新,癌症疫苗的发展经历了多个重要阶段。

Arthritis Res Ther:接种疫苗是否会增加患系统性红斑狼疮(SLE)的风险?

大部分疫苗,包括常见的流感和新冠疫苗,与SLE风险之间没有关联。

无复发生存16个月!《自然-医学》:通用癌症疫苗,突破“难以成药”

加州大学洛杉矶分校医疗中心正在进行的一项临床试验信息引起了Rahma及其家人的关注,这项试验正在评估一种手术后使用的“现货型”的疫苗,目的是预防或延迟癌症高危患者病情复发。

JCC:重组带状疱疹疫苗(RZV)对降低炎症性肠病患者发生带状疱疹(HZ)有效

炎症性肠病是一种非特异性的慢性肠道炎性疾病,主要包括溃疡性结肠炎和克罗恩病,前者主要损害结肠和直肠,后者可损害从口腔到肛门之间的任意胃肠道部位。

新冠病毒感染及疫苗影响转基因吗?5314名参与者的数据分析!

本研究旨在评估接受COVID-19疫苗或经历SARS-CoV-2感染是否影响育龄妇女的月经周期,以及如有影响,其造成月经不规律的持续时间!

永远相信好的事情即将发生,疫苗可以延迟KRAS突变胰腺癌、肠癌的复发!

尽管存在KRAS突变的胰腺癌和肠癌办法很少,但是我们感谢这个世界存在不断钻研的科学家,最近发布在《自然医学》杂志的研究表明,一种疫苗具有预防KRAS突变的胰腺癌、结直肠癌复发的潜力。